Prelude Therapeutics Stock Performance
| PRLD Stock | USD 1.85 0.05 2.63% |
The company holds a Beta of -2.06, which implies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Prelude Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, Prelude Therapeutics is expected to outperform it. At this point, Prelude Therapeutics has a negative expected return of -0.46%. Please make sure to check Prelude Therapeutics' semi variance, day typical price, and the relationship between the maximum drawdown and accumulation distribution , to decide if Prelude Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Prelude Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's essential indicators remain rather sound which may send shares a bit higher in March 2026. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
1 | Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | 11/12/2025 |
2 | PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm | 11/19/2025 |
3 | Beat the Market the Zacks Way Goldman Sachs, Micron, Prelude in Focus - TradingView | 11/24/2025 |
4 | Redhill Biopharma and Prelude Therapeutics Financial Comparison | 12/08/2025 |
5 | Prelude Therapeutics Stock Price Up 2.1 percent - Whats Next - MarketBeat | 12/24/2025 |
6 | Bullish Prelude Therapeutics Insiders Rewarded As Their Investment Rises To US2.75m | 12/30/2025 |
7 | Prelude Therapeutics Incorporateds biggest owners are retail investors who got richer after stock soared 12 percent last week | 01/26/2026 |
| Begin Period Cash Flow | 29.3 M | |
| Total Cashflows From Investing Activities | 90.2 M |
Prelude Therapeutics Relative Risk vs. Return Landscape
If you would invest 398.00 in Prelude Therapeutics on November 2, 2025 and sell it today you would lose (213.00) from holding Prelude Therapeutics or give up 53.52% of portfolio value over 90 days. Prelude Therapeutics is currently does not generate positive expected returns and assumes 11.0948% risk (volatility on return distribution) over the 90 days horizon. In different words, 99% of stocks are less volatile than Prelude, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Prelude Therapeutics Target Price Odds to finish over Current Price
The tendency of Prelude Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 1.85 | 90 days | 1.85 | about 55.46 |
Based on a normal probability distribution, the odds of Prelude Therapeutics to move above the current price in 90 days from now is about 55.46 (This Prelude Therapeutics probability density function shows the probability of Prelude Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Prelude Therapeutics has a beta of -2.06 indicating as returns on its benchmark rise, returns on holding Prelude Therapeutics are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, Prelude Therapeutics is expected to outperform its benchmark. Moreover Prelude Therapeutics has an alpha of 1.8034, implying that it can generate a 1.8 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Prelude Therapeutics Price Density |
| Price |
Predictive Modules for Prelude Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Prelude Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Prelude Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Prelude Therapeutics is not an exception. The market had few large corrections towards the Prelude Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Prelude Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Prelude Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 1.80 | |
β | Beta against Dow Jones | -2.06 | |
σ | Overall volatility | 0.51 | |
Ir | Information ratio | 0.08 |
Prelude Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Prelude Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Prelude Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Prelude Therapeutics generated a negative expected return over the last 90 days | |
| Prelude Therapeutics has high historical volatility and very poor performance | |
| Prelude Therapeutics may become a speculative penny stock | |
| Prelude Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 7 M. Net Loss for the year was (127.17 M) with profit before overhead, payroll, taxes, and interest of 10.5 M. | |
| Prelude Therapeutics currently holds about 246.3 M in cash with (102.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.19, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 55.0% of the company shares are owned by institutional investors | |
| Latest headline from simplywall.st: Prelude Therapeutics Incorporateds biggest owners are retail investors who got richer after stock soared 12 percent last week |
Prelude Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Prelude Stock often depends not only on the future outlook of the current and potential Prelude Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Prelude Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 75.8 M | |
| Cash And Short Term Investments | 133.6 M |
Prelude Therapeutics Fundamentals Growth
Prelude Stock prices reflect investors' perceptions of the future prospects and financial health of Prelude Therapeutics, and Prelude Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Prelude Stock performance.
| Return On Equity | -1.04 | ||||
| Return On Asset | -0.52 | ||||
| Operating Margin | (3.14) % | ||||
| Current Valuation | 80.46 M | ||||
| Shares Outstanding | 43.77 M | ||||
| Price To Book | 2.01 X | ||||
| Price To Sales | 11.08 X | ||||
| Revenue | 7 M | ||||
| Gross Profit | 10.5 M | ||||
| EBITDA | (137.94 M) | ||||
| Net Income | (127.17 M) | ||||
| Cash And Equivalents | 246.3 M | ||||
| Cash Per Share | 5.19 X | ||||
| Total Debt | 18.02 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 15.73 X | ||||
| Book Value Per Share | 0.77 X | ||||
| Cash Flow From Operations | (102.89 M) | ||||
| Earnings Per Share | (1.47) X | ||||
| Market Capitalization | 116.3 M | ||||
| Total Asset | 175.51 M | ||||
| Retained Earnings | (583.56 M) | ||||
| Working Capital | 110.25 M | ||||
About Prelude Therapeutics Performance
By analyzing Prelude Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Prelude Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Prelude Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Prelude Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.65) | (0.68) | |
| Return On Capital Employed | (0.84) | (0.88) | |
| Return On Assets | (0.65) | (0.68) | |
| Return On Equity | (1.11) | (1.06) |
Things to note about Prelude Therapeutics performance evaluation
Checking the ongoing alerts about Prelude Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Prelude Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Prelude Therapeutics generated a negative expected return over the last 90 days | |
| Prelude Therapeutics has high historical volatility and very poor performance | |
| Prelude Therapeutics may become a speculative penny stock | |
| Prelude Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 7 M. Net Loss for the year was (127.17 M) with profit before overhead, payroll, taxes, and interest of 10.5 M. | |
| Prelude Therapeutics currently holds about 246.3 M in cash with (102.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.19, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 55.0% of the company shares are owned by institutional investors | |
| Latest headline from simplywall.st: Prelude Therapeutics Incorporateds biggest owners are retail investors who got richer after stock soared 12 percent last week |
- Analyzing Prelude Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Prelude Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Prelude Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Prelude Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Prelude Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Prelude Therapeutics' stock. These opinions can provide insight into Prelude Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Prelude Stock analysis
When running Prelude Therapeutics' price analysis, check to measure Prelude Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Prelude Therapeutics is operating at the current time. Most of Prelude Therapeutics' value examination focuses on studying past and present price action to predict the probability of Prelude Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Prelude Therapeutics' price. Additionally, you may evaluate how the addition of Prelude Therapeutics to your portfolios can decrease your overall portfolio volatility.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |